DepressionNCT01327417
Cortical/Subcortical Circuits in Late-Life Depression
An observational study of Depression, run by University of Illinois Chicago at 1 site in United States.
Trial summary
The purpose of the study is to examine the relationship between brain structure and depression in adults aged 60 or older. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain. Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Depression
- How many people
- 400 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Sep 2009to Sep 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: * Geriatric Medicine and Psychiatry clinics within the UIC Medical Center. Patients with mood and other psychiatric disturbances are frequently referred by physicians from both geriatric medicine and family medicine for a consultation and sometimes for ongoing psychiatric care. * Community outreach efforts and recruitment through advertising in newsletters, local newspapers
Who may be able to join
- Age: 60 years or greater
- Diagnosis of major depressive disorder using standard diagnostic and statistical manual (DSM) criteria
- Score of 15 or greater on the 17-item Hamilton Depression rating scale
- Mini Mental Status Exam score of 24 or greater
- No evidence of clinical dementia or any other clinical brain disorder
- Free of psychotropic/psychoactive medications for at least 2 weeks
Who cannot join
- Presence of dementia or any other clinical brain disorder (Parkinson's, Alzheimer's)
- History of progressive cognitive decline and/or Mini Mental Status Exam score of less than 24
- Lifetime diagnosis of substance abuse
- Unstable medical illness (grade 4 on the Cumulative Illness Rating Scale)
- Presence of any metallic implant that would preclude an MRI scan (pacemaker, etc.)
- Concurrent Axis 1 disorder (schizophrenia, bipolar)
Show all 17Show fewer
- Psychotropic medication implicated in depression i.e. Reserpine, Alpha methyl dopa, Beta blockers, multiple long acting benzodiazepines (valium, flurazepam, chlordiazepoxide), neuroleptics;
- Seizure disorder
- Stroke/Transient Ischemic Attack
- Central nervous system disorder (Parkinson's disease, multiple sclerosis)
- Trauma to head/Loss of Consciousness
- Claustrophobia
- Eating disorder (anorexia, bulimia)
- Weight of over 350 pounds
- Learning disorder (dyslexia, ADHD)
- Psychosis, panic or anxiety disorder outside the context of depression
- Mood stabilizing agents such as lithium and Divalproex sodium and antidepressants - as they have been shown to impact on brain levels of NAA, Ch and Ml
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of the study is to examine the relationship between brain structure and depression in adults aged 60 or older. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain.
Read the detailed description
Major depressive disorder (MDD) and other clinically significant forms of "minor depression" are among the most common mental disorders in the elderly. Data from the Epidemiologic Catchment Area Studies indicate that in the community dwelling elderly, the prevalence of MDD is approximately 1-2 percent. The prevalence of dysthymia and "clinically significant" depressive symptoms is estimated to be 2-3% and 5-10% respectively. Clinically significant mood disorders are responsible for considerable medical and psychosocial morbidity. These include frequent medical and psychiatric hospitalizations, visits to the emergency room, suicide attempts, and use of alcohol, and other prescription medications with psychotropic effects. The clinical impact of these disorders is comparable to those caused by other chronic medical disorders.
The vast majority of patients with mood disorders are managed at ambulatory care/primary care settings around the country. Ambulatory care clinics have become "defacto" settings for the diagnosis and management of psychiatric problems, especially in the elderly. Depression, particularly in the elderly, is associated with several chronic medical illnesses including malignancies, chronic obstructive pulmonary disease, and gastrointestinal, vascular, autoimmune and demyelinating disorders. Acknowledging the overall robust association between medical illness and mood disorders, the NIH consensus statement on depression in the elderly states, "The hallmark of depression in late-life is its association with medical comorbidity." While the precise mechanisms by which coexisting medical illnesses contribute to depression remain unclear, neuroanatomical, vascular, immunologic, psychosocial and /or a combination of these mechanisms have been invoked as possible pathways by which medical disorders may lead to depression in the elderly.
Late-life MDD is characterized by 1) Neuroanatomical changes in neocortical and subcortical regions of the brain. These principally comprise a decrease in focal brain volumes and an increase in the volume of high intensity lesions in the parenchyma; 2) The increase in high intensity lesions occurs largely, though not exclusively, in the white matter; 3) Preliminary studies suggest that there are abnormalities in white matter regions and tracts even in areas that appear normal in MR images in patients with late-life MDD when compared with controls; 4) Biochemical and biophysical changes in the white matter are likely related to the pathophysiology of major psychiatric disorders independent of the impact of cerebrovascular disease/risk factors.
TRIAL OBJECTIVES AND PURPOSE
Specific Aim 1: To estimate absolute levels and ratios (metabolite/creatine) of NAA, Ch and Ml bilaterally in the dorsolateral white matter and subcortical nuclei in patients with MDD and non-depressed controls.
Hypothesis: Absolute levels and ratios of Ch and Ml will be higher and levels of NAA will be lower in the dorsolateral white matter and the subcortical nuclei in patients with MDD when compared with controls.
Specific Aim 2: To estimate magnetization transfer ratios (MTR) bilaterally in the frontal white matter/head of the caudate nucleus and the putamen in patients with MDD and controls and to examine the relationship between MTR and MRS measures in the dorsolateral white matter. Hypothesis a: MTR will be significantly lower in normal appearing dorsolateral white matter regions and subcortical nuclei (caudate nucleus and putamen) in patients with MDD when compared with controls.
Hypothesis b: There will be an inverse relationship between MTR and normalized levels of Ml in patients diagnosed with MDD in the dorsolateral white matter bilaterally.
Specific Aim 3: To examine the neurocognitive correlates of frontal and striatal compromise identified using MRS and MT ratio measures in patients with MDD and controls. The associations between NAA and a global cognitive scale and MT ratios from the bilateral dorsolateral white matter and subcortical nuclei and subscales targeted to dorsolateral and striatal cognitive functioning will be examined.
Hypothesis a: Among healthy and depressed elderly, NAA/Cr with be positively related to a global scale of cognitive function.
Hypothesis b: Among healthy and depressed elderly, MT ratios of the dorsolateral cortices will be positively related to a subscale of dorsolateral function (working memory, executive function, nonverbal recall).
Hypothesis c: Among healthy and depressed elderly, MT ratios of subcortical nuclei will be positively related to a subscale of striatal function (processing, learning).
Exploratory analyses: In addition to the specific aims above, the investigators will conduct two three exploratory analyses.
Analysis 1: A more finely grained analysis in which the investigators examine the relationship of NAA, Ml and Cho ratios to dorsolateral and striatal subscales after examining their relationship to global cognitive function. The investigators will also study the relationship of the relative concentrations of NAA to Ml (NAA/MI) and Ch (NAA/Ch) to global and regional subscales. In addition, the preliminary MTR data suggest that there may be laterally effects, which the investigators will examine.
Analysis 2: A comparison of blood samples of the healthy versus depressed subject groups, to see if there is evidence of differences in the neurotransmitter system, hypothalamic-pituitary-adrenals (HAP) axis, and immune function between these two groups of elderly persons.
Analysis 3: To examine whether neuroimaging and cognitive measures associated with major depression are reversed by antidepressant treatment.
- Conditions
- Depression
- Keywords
- Depression
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Depressed | Patients with Major Depressive Disorder | |
| Healthy Controls | Not described |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2011 (estimated)
- Study start22 Sep 2009
- Primary completion19 Aug 2014
- Study completionSep 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Illinois Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Sponsor
- Investigators
- Anand Kumar, MD, Principal investigator, University of Illinois Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01327417
- Sponsor's protocol ID
- 2009-0613
- Other IDs
- R01MH073989
- Status last verified
- May 2025
- First submitted
- 30 Mar 2011
- Last updated
- 20 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Ballmaier M, Narr KL, Toga AW, Elderkin-Thompson V, Thompson PM, Hamilton L, Haroon E, Pham D, Heinz A, Kumar A. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression. Am J Psychiatry. 2008 Feb;165(2):229-37. doi: 10.1176/appi.ajp.2007.07030506. Epub 2007 Nov 6.
PubMed 17986679Ballmaier M, Kumar A, Elderkin-Thompson V, Narr KL, Luders E, Thompson PM, Hojatkashani C, Pham D, Heinz A, Toga AW. Mapping callosal morphology in early- and late-onset elderly depression: an index of distinct changes in cortical connectivity. Neuropsychopharmacology. 2008 Jun;33(7):1528-36. doi: 10.1038/sj.npp.1301538. Epub 2007 Aug 22.
PubMed 17712348Lavretsky H, Ballmaier M, Pham D, Toga A, Kumar A. Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. Am J Geriatr Psychiatry. 2007 May;15(5):386-94. doi: 10.1097/JGP.0b013e3180325a16.
PubMed 17463189Kumar A, Ajilore O. Magnetic resonance imaging and late-life depression: potential biomarkers in the era of personalized medicine. Am J Psychiatry. 2008 Feb;165(2):166-8. doi: 10.1176/appi.ajp.2007.07111771. No abstract available.
PubMed 18245182
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cortical/Subcortical Circuits in Late-Life Depression
- ClinicalTrials.gov ID
- NCT01327417
- Acronym / sponsor ID
- 2009-0613
- Conditions
- Depression
- Keywords
- Depression
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- University of Illinois ChicagoUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- 22 Sep 2009 (actual)
- Primary completion
- 19 Aug 2014 (actual)
- Study completion
- Sep 2014 (actual)
- First posted
- 1 Apr 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to examine the relationship between brain structure and depression in adults aged 60 or older. This relationship is determined using magnetic resonance imaging technology (MRI), a scanner with a magnet that is used to create images of the brain.
Detailed description
Major depressive disorder (MDD) and other clinically significant forms of "minor depression" are among the most common mental disorders in the elderly. Data from the Epidemiologic Catchment Area Studies indicate that in the community dwelling elderly, the prevalence of MDD is approximately 1-2 percent. The prevalence of dysthymia and "clinically significant" depressive symptoms is estimated to be 2-3% and 5-10% respectively. Clinically significant mood disorders are responsible for considerable medical and psychosocial morbidity. These include frequent medical and psychiatric hospitalizations, visits to the emergency room, suicide attempts, and use of alcohol, and other prescription medications with psychotropic effects. The clinical impact of these disorders is comparable to those caused by other chronic medical disorders.
The vast majority of patients with mood disorders are managed at ambulatory care/primary care settings around the country. Ambulatory care clinics have become "defacto" settings for the diagnosis and management of psychiatric problems, especially in the elderly. Depression, particularly in the elderly, is associated with several chronic medical illnesses including malignancies, chronic obstructive pulmonary disease, and gastrointestinal, vascular, autoimmune and demyelinating disorders. Acknowledging the overall robust association between medical illness and mood disorders, the NIH consensus statement on depression in the elderly states, "The hallmark of depression in late-life is its association with medical comorbidity." While the precise mechanisms by which coexisting medical illnesses contribute to depression remain unclear, neuroanatomical, vascular, immunologic, psychosocial and /or a combination of these mechanisms have been invoked as possible pathways by which medical disorders may lead to depression in the elderly.
Late-life MDD is characterized by 1) Neuroanatomical changes in neocortical and subcortical regions of the brain. These principally comprise a decrease in focal brain volumes and an increase in the volume of high intensity lesions in the parenchyma; 2) The increase in high intensity lesions occurs largely, though not exclusively, in the white matter; 3) Preliminary studies suggest that there are abnormalities in white matter regions and tracts even in areas that appear normal in MR images in patients with late-life MDD when compared with controls; 4) Biochemical and biophysical changes in the white matter are likely related to the pathophysiology of major psychiatric disorders independent of the impact of cerebrovascular disease/risk factors.
TRIAL OBJECTIVES AND PURPOSE
Specific Aim 1: To estimate absolute levels and ratios (metabolite/creatine) of NAA, Ch and Ml bilaterally in the dorsolateral white matter and subcortical nuclei in patients with MDD and non-depressed controls.
Hypothesis: Absolute levels and ratios of Ch and Ml will be higher and levels of NAA will be lower in the dorsolateral white matter and the subcortical nuclei in patients with MDD when compared with controls.
Specific Aim 2: To estimate magnetization transfer ratios (MTR) bilaterally in the frontal white matter/head of the caudate nucleus and the putamen in patients with MDD and controls and to examine the relationship between MTR and MRS measures in the dorsolateral white matter. Hypothesis a: MTR will be significantly lower in normal appearing dorsolateral white matter regions and subcortical nuclei (caudate nucleus and putamen) in patients with MDD when compared with controls.
Hypothesis b: There will be an inverse relationship between MTR and normalized levels of Ml in patients diagnosed with MDD in the dorsolateral white matter bilaterally.
Specific Aim 3: To examine the neurocognitive correlates of frontal and striatal compromise identified using MRS and MT ratio measures in patients with MDD and controls. The associations between NAA and a global cognitive scale and MT ratios from the bilateral dorsolateral white matter and subcortical nuclei and subscales targeted to dorsolateral and striatal cognitive functioning will be examined.
Hypothesis a: Among healthy and depressed elderly, NAA/Cr with be positively related to a global scale of cognitive function.
Hypothesis b: Among healthy and depressed elderly, MT ratios of the dorsolateral cortices will be positively related to a subscale of dorsolateral function (working memory, executive function, nonverbal recall).
Hypothesis c: Among healthy and depressed elderly, MT ratios of subcortical nuclei will be positively related to a subscale of striatal function (processing, learning).
Exploratory analyses: In addition to the specific aims above, the investigators will conduct two three exploratory analyses.
Analysis 1: A more finely grained analysis in which the investigators examine the relationship of NAA, Ml and Cho ratios to dorsolateral and striatal subscales after examining their relationship to global cognitive function. The investigators will also study the relationship of the relative concentrations of NAA to Ml (NAA/MI) and Ch (NAA/Ch) to global and regional subscales. In addition, the preliminary MTR data suggest that there may be laterally effects, which the investigators will examine.
Analysis 2: A comparison of blood samples of the healthy versus depressed subject groups, to see if there is evidence of differences in the neurotransmitter system, hypothalamic-pituitary-adrenals (HAP) axis, and immune function between these two groups of elderly persons.
Analysis 3: To examine whether neuroimaging and cognitive measures associated with major depression are reversed by antidepressant treatment.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Depressed | – | –Patients with Major Depressive Disorder |
| Healthy Controls | – | – |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- * Geriatric Medicine and Psychiatry clinics within the UIC Medical Center. Patients with mood and other psychiatric disturbances are frequently referred by physicians from both geriatric medicine and family medicine for a consultation and sometimes for ongoing psychiatric care. * Community outreach efforts and recruitment through advertising in newsletters, local newspapers
Key inclusion criteria (6 listed)
- Age: 60 years or greater
- Diagnosis of major depressive disorder using standard diagnostic and statistical manual (DSM) criteria
- Score of 15 or greater on the 17-item Hamilton Depression rating scale
- Mini Mental Status Exam score of 24 or greater
- No evidence of clinical dementia or any other clinical brain disorder
Key exclusion criteria (17 listed)
- Presence of dementia or any other clinical brain disorder (Parkinson's, Alzheimer's)
- History of progressive cognitive decline and/or Mini Mental Status Exam score of less than 24
- Lifetime diagnosis of substance abuse
- Unstable medical illness (grade 4 on the Cumulative Illness Rating Scale)
- Presence of any metallic implant that would preclude an MRI scan (pacemaker, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2025.
- Background: PubMed 17986679Ballmaier M, Narr KL, Toga AW, Elderkin-Thompson V, Thompson PM, Hamilton L, Haroon E, Pham D, Heinz A, Kumar A. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression. Am J Psychiatry. 2008 Feb;165(2):229-37. doi: 10.1176/appi.ajp.2007.07030506. Epub 2007 Nov 6.
- Background: PubMed 17712348Ballmaier M, Kumar A, Elderkin-Thompson V, Narr KL, Luders E, Thompson PM, Hojatkashani C, Pham D, Heinz A, Toga AW. Mapping callosal morphology in early- and late-onset elderly depression: an index of distinct changes in cortical connectivity. Neuropsychopharmacology. 2008 Jun;33(7):1528-36. doi: 10.1038/sj.npp.1301538. Epub 2007 Aug 22.
- Background: PubMed 17463189Lavretsky H, Ballmaier M, Pham D, Toga A, Kumar A. Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. Am J Geriatr Psychiatry. 2007 May;15(5):386-94. doi: 10.1097/JGP.0b013e3180325a16.
- Results publication: PubMed 18245182Kumar A, Ajilore O. Magnetic resonance imaging and late-life depression: potential biomarkers in the era of personalized medicine. Am J Psychiatry. 2008 Feb;165(2):166-8. doi: 10.1176/appi.ajp.2007.07111771. No abstract available.
- Related InfoLink provided by the sponsor.
Related trials for Depression
Not yet recruiting
Mandala Coloring in Late Pregnancy
Pregnancy, Anxiety
Not yet recruitingObservational study
Ecological Momentary Assessment of State-Dependent Decision-Making and Metacognition Across a Psychopathology Continuum
Depression, Anxiety
Not yet recruiting
Adapting the ESTEEM Intervention to Improve Mental Health and PrEP Uptake Among Men at Risk of HIV
PrEP Use
Recruiting
Cancer Pain Management Using a Web-based Intervention
Cancer of Breast, Depressive Symptoms
Active, not recruiting
Improving Student Mental Health Through a Universal Trauma-Informed Intervention
Anxiety Symptoms, Post-traumatic Stress Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anand Kumar, MD principal investigator
University of Illinois Chicago
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Depression, run by University of Illinois Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01327417, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2025.